AGAshni Goshrani

Ashni Goshrani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ashni Goshrani has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Elif Ilhan Ekinci

    Australian Centre for Accelerating Diabetes Innovations (ACADI) The University of Melbourne Melbourne Victoria Australia

    2 shared publications
  • Rose Lin

    Endocrinology Department, Eastern Health 2 , Melbourne, Victoria, Australia

    2 shared publications
  • Andrew Farmer

    Nuffield Department of Primary Care Health Sciences, University of Oxford 8 , Oxford, U.K.

    1 shared publication
  • Christine Sommerville

    Department of Medicine, Melbourne Medical School, The University of Melbourne 3 , Melbourne, Victoria, Australia

    1 shared publication
  • David Norman O'Neal

    Department of Endocrinology and Diabetes, St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia

    1 shared publication
  • David O’NEal

    Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne 4 , Carlton, Victoria, Australia

    1 shared publication

Latest Publications

  • The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review

    by Ashni Goshrani, Rose Lin, Leonid Churilov, Michele Gaca, Christine Sommerville, Andrew Farmer, Kamlesh Khunti, Elizabeth Holmes-Truscott, Negar Naderpoor, David O’NEal, et al.

    BACKGROUND: Adaptive and master protocol clinical trials offer significant advantages for diabetes research, including enhanced efficiency and personalized treatment strategies. PURPOSE: This scoping review aimed to systematically map the use of adaptive and master protocol designs in interventional trials for type 1 and type 2 diabetes, identify research gaps, and highlight opportunities for broader implementation. DATA SOURCES: A systematic literature search was performed using MEDLINE, Embase, CENTRAL, Emcare, Global Health, Web of Science, and clinical trial registries. Gray literature searches complemented database findings. STUDY SELECTION: Studies using adaptive, platform, basket, or umbrella trial designs in people with type 1 or type 2 diabetes were included. DATA EXTRACTION: Data were charted using a standardized form. Extracted variables included diabetes type, trial design, adaptive features, interventions, end points, and key findings. DATA SYNTHESIS: Of 396 articles screened, 6 published adaptive trials met the inclusion criteria: 3 in type 1 diabetes, 1 in type 2 diabetes, and 2 in diabetes-related neuropathy. Most used adaptive features for dose finding, response-adaptive randomization, and sample size reestimation. No published platform, basket, or umbrella trials were identified. Six ongoing adaptive trials in type 1 diabetes were identified through registry searches, four under an adaptive platform master protocol. LIMITATIONS: Despite a comprehensive search, some gray literature and unpublished studies may have been missed. Risk of bias was not assessed, consistent with scoping review methodology. CONCLUSIONS: Adaptive and master protocol trials remain rare in diabetes. Overcoming barriers through targeted training and awareness, robust regulatory frameworks, and strategic incentives could support broader adoption.

  • Open Access

    Time in range—A new gold standard in type 2 diabetes research?

    by Ashni Goshrani, Rose Lin, David O'NEal, Elif I. Ekinci

    Glycated haemoglobin (HbA1c) is currently the gold standard outcome measure for type 2 diabetes trials. Time in range is a continuous glucose monitoring (CGM) metric defined as the proportion of time in euglycemia (3.9–10.0 mmol/L) and may be valuable not only in type 1 diabetes clinical trials but also as an endpoint in type 2 diabetes trials. This narrative review aimed to assess the relative merits of time in range versus HbA1c as outcome measures for type 2 diabetes studies. It reviews the strengths and limitations of time in range as an outcome measure and evaluates studies in type 2 diabetes that have used time in range as a primary or secondary outcome measure. A literature search was conducted on PubMed and MEDLINE databases using key terms “time in range” AND “diabetes” OR “type 2 diabetes mellitus”. Further evidence was obtained from relevant references of retrieved articles. Literature search identified 247 papers, of which 110 were included in this review. These included a broad range of articles, including 45 randomized trials using time in range as an outcome measure in patients with type 2 diabetes, as well as papers validating time in range. Time in range provides valuable and clinically relevant information and should be used as an important endpoint in type 2 diabetes in clinical trial settings, in conjunction with HbA1c.